A Summerville life-sciences firm that develops and manufactures health supplements has finalized its first acquisition since becoming a publicly traded company.

Thorne HealthTech Inc. announced Feb. 3 that it bought Arizona-based PreCon Health Inc. in a deal valued at $5 million. The sale closed Tuesday.

The companies had been working together under a partnership since April 2021 to manufacture and commercialize what they called the “first multi-ingredient dietary supplement formulated to support pre- and post-impact brain health.”

The trade name of the product is SynaQuell. It underwent clinical trials at the Mayo Clinic and is designed for “contact sport athletes and others sustaining frequent head impacts,” according to an overview of a year-long test with ice hockey players.

“I couldn’t be prouder of the milestones achieved … and am confident in Thorne’s ability to maximize the potential of these products,” said Dr. David Dodick, emeritus professor of neurology at the Mayo Clinic and former chairman of PreCon.

Thorne did not respond to a request for comment Friday. In a written statement, CEO Paul Jacobson said that the 2021 partnership with PreCon “laid the foundation” for this week’s acquisition, which provides the Lowcountry company with access to other products and intellectual property that can be used in future research-and-development efforts.

“There is a significant need to continue developing solutions that address impact-related brain health,” he said.

Included in the deal is PreCon’s medical and scientific advisory board made up of physicians, researchers, retired military personnel and former professional athletes.

An 8-ounce jar of SynaQuell containing about 60 helpings of the supplement is priced at $62 on Thorne’s website. A more expensive “plus” version also is available. 

Thorne announced it was moving most of its key business operations to Berkeley County about six years ago after outgrowing its manufacturing site in northern Idaho. The deal included a $35 million capital investment and 350 jobs. The life-science company has since expanded its physical footprint and payroll in the region.

Thorne listed its shares on the Nasdaq exchange a few months after it began working with PreCon. Through the first nine months of last year, it reported that net income rose to $3.1 million from $476,000 for the same period of 2021. Sales were up 25 percent to $169 million through Sept. 30. 

The company’s stock has yet to climb back to its initial public offering price of $10 in September 2021. Shares of Thorne fell slightly Friday to close at $4.71.